Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Vitamin C  COVID-19 treatment studies for Vitamin C  C19 studies: Vitamin C  Vitamin C   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Case 18% Improvement Relative Risk Case (b) 29% Behera et al. Vitamin C for COVID-19 Prophylaxis Does vitamin C reduce COVID-19 infections? Retrospective 215 patients in India Fewer cases with vitamin C (not stat. sig., p=0.58) Behera et al., PLoS ONE, doi:10.1371/journal.pone.0247163 Favors vitamin C Favors control

Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: A matched case-control study

Behera et al., PLoS ONE, doi:10.1371/journal.pone.0247163 (date from earlier preprint)
Behera et al., Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: A matched.., PLoS ONE, doi:10.1371/journal.pone.0247163 (date from earlier preprint)
Nov 2020   Source   PDF  
  All Studies   Meta
Retrospective matched case-control prophylaxis study for HCQ, ivermectin, and vitamin C with 372 healthcare workers, showing lower COVID-19 incidence for all treatments, with statistical significance reached for ivermectin.
HCQ OR 0.56, p = 0.29
Ivermectin OR 0.27, p < 0.001
Vitamin C OR 0.82, p = 0.58
This is the 5th of 61 COVID-19 controlled studies for vitamin C, which collectively show efficacy with p=0.00000098. 15 studies are RCTs, which show efficacy with p=0.00013.
This study includes vitamin C, ivermectin, and HCQ.
risk of case, 18.0% lower, OR 0.82, p = 0.58, treatment 29 of 67 (43.3%) cases, 38 of 148 (25.7%) controls, adjusted per study, case control OR, model 2 conditional logistic regression.
risk of case, 29.0% lower, OR 0.71, p = 0.24, treatment 29 of 67 (43.3%) cases, 38 of 148 (25.7%) controls, adjusted per study, case control OR, matched pair analysis.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Behera et al., 3 Nov 2020, retrospective, India, peer-reviewed, 13 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin CAll
Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: A matched case-control study
Priyamadhaba Behera, Binod Kumar Patro, Arvind Kumar Singh, Pradnya Dilip Chandanshive, Ravikumar S. R., Somen Kumar Pradhan, Siva Santosh Kumar Pentapati, Gitanjali Batmanabane, Prasanta Raghab Mohapatra, Biswa Mohan Padhy, Shakti Kumar Bal, Sudipta Ranjan Singh, Rashmi Ranjan Mohanty
PLOS ONE, doi:10.1371/journal.pone.0247163
Background Ivermectin is one among several potential drugs explored for its therapeutic and preventive role in SARS-CoV-2 infection. The study was aimed to explore the association between ivermectin prophylaxis and the development of SARS-CoV-2 infection among healthcare workers. Methods A hospital-based matched case-control study was conducted among healthcare workers of AIIMS Bhubaneswar, India, from September to October 2020. Profession, gender, age and date of diagnosis were matched for 186 case-control pairs. Cases and controls were healthcare workers who tested positive and negative, respectively, for COVID-19 by RT-PCR. Exposure was defined as the intake of ivermectin and/or hydroxychloroquine and/or vitamin-C and/or other prophylaxis for COVID-19. Data collection and entry was done in Epicol-lect5, and analysis was performed using STATA version 13. Conditional logistic regression models were used to describe the associated factors for SARS-CoV-2 infection. Results Ivermectin prophylaxis was taken by 76 controls and 41 cases. Two-dose ivermectin prophylaxis (AOR 0.27, 95% CI, 0.15-0.51) was associated with a 73% reduction of SARS-CoV-2 infection among healthcare workers for the following month. Those involved in physical activity (AOR 3.06 95% CI, 1.18-7.93) for more than an hour/day were more likely to contract SARS-CoV-2 infection. Type of household, COVID duty, single-dose ivermectin
Supporting information S1 Appendix. Questionnaire used in the study (English and Odia language). (PDF) S1 Protocol. Study protocol. (DOC) Author Contributions
Ağalar, Engin, Protective measures for COVID-19 for healthcare providers and laboratory personnel, Turk J Med Sci, doi:10.3906/sag-2004-132
Biancatelli, Berrill, Catravas, Marik, Quercetin and vitamin C: an experimental, synergistic therapy for the prevention and treatment of SARS-CoV-2 related disease (COVID-19), Front Immunol, doi:10.3389/fimmu.2020.01451
Boulware, Pullen, Bangdiwala, Pastick, Lofgren et al., A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19, N Engl J Med, doi:10.1056/NEJMoa2016638
Caly, Druce, Catton, Jans, Wagstaff, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Res, doi:10.1016/j.antiviral.2020.104787
Chang, Figueredo, COVID-19: ivermectin prophylaxis in adult contacts. First Report on Health Personnel and Post-Exposure Prophylaxis, Research Gate
Cheng, Kogan, Davis, Ascorbate as Prophylaxis and Therapy for COVID-19-Update From Shanghai and US Medical Institutions, Glob Adv Health Med, doi:10.1177/2164956120934768
Feyaerts, Luyten, Vitamin C as prophylaxis and adjunctive medical treatment for COVID-19? Nutrition, doi:10.1016/j.nut.2020.110948
Galvin, Li, Malwade, Syed-Abdul, COVID-19 preventive measures showing an unintended decline in infectious diseases in Taiwan, Int J Infect Dis, doi:10.1016/j.ijid.2020.06.062
Galvis, Spinelli, Tello, Sossa, Higuera et al., Hydroxychloroquine as prophylaxis for coronavirus SARS-CoV-2 infection: review of the ongoing clinical trials, Arch Bronconeumol, doi:10.1016/j.arbres.2020.05.008
Geremia, Vito, Gunnella, Fiore, Princic et al., A Case of Vasculities-Like Skin Eruption Associated With COVID-19, Infectious Diseases in Clinical Practice
Guarneri, Rullo, Pavone, Berretta, Ceccarelli et al., Silent COVID-19: what your skin can reveal, Infectious Diseases, doi:10.1016/S1473-3099%2820%2930402-3
Lahiri, Jha, Bhattacharya, Ray, Chakraborty, Effectiveness of preventive measures against COVID-19: A systematic review of In Silico modeling studies in indian context, Indian J Public Health, doi:10.4103/ijph.IJPH%5F464%5F20
Mahmud, A Phase III Trial to Promote Recovery From Covid 19 With Combined Doxycycline and Ivermectin Along Standard Care
Nmaster, Version2.0-Sample Size Software
Qian, Jiang, COVID-19 and social distancing, Z Gesundh Wiss, doi:10.1007/s10389-020-01321-z
Rajter, Sherman, Fatteh, Vogel, Sacks et al., Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID-19 (ICON study), Chest, doi:10.1016/j.chest.2020.10.009
Sant'ana, Imoto, Amorim, Taminato, Peccin et al., Infection and death in healthcare workers due to COVID-19: a systematic review, Acta Paul Enferm
Shouman, Use of Ivermectin as a Prophylactic Option in Asymptomatic Family Close Contact for Patient With COVID-19
Teslya, Pham, Godijk, Kretzschmar, Bootsma et al., Impact of self-imposed prevention measures and short-term government intervention on mitigating and delaying a COVID-19 epidemic: A modelling study, PLOS Medicine, doi:
Vaira, Deiana, Fois, Pirina, Madeddu et al., Objective evaluation of anosmia and ageusia in COVID-19 patients: Single-center experience on 72 cases
Vaira, Hopkins, Salzano, Petrocelli, Melis et al., Olfactory and gustatory function impairment in COVID-19 patients: Italian objective multicenter-study, Head & Neck, doi:10.1002/hed.26269
Vito, Geremia, Fiore, Princic, Babudieri et al., Clinical features, laboratory findings and predictors of death in hospitalized patients with COVID-19 in Sardinia, Italy, Eur Rev Med Pharmacol Sci, doi:10.26355/eurrev%5F202007%5F22291
Wang, Pasco, Du, Petty, Fox et al., Impact of social distancing measures on coronavirus disease healthcare demand, central Texas, USA, Emerg Infect Dis, doi:10.3201/eid2610.201702
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop